Lyra Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	23.75	33.94	46.08	74.92	10.14	24.22
Short-Term Investments	80.4	65.34	0	0	0	0
Cash & Cash Equivalents	104.15	99.29	46.08	74.92	10.14	24.22
Cash Growth	4.89%	115.48%	-38.50%	639.09%	-58.14%	-
Receivables	0	0	0	0	0	0.17
Other Current Assets	0.68	1.54	1.84	1	-0.02	0.54
Total Current Assets	104.82	100.83	47.92	75.92	10.12	24.93
Property, Plant & Equipment	35.28	4.47	5.86	4.47	3.42	0.1
Other Long-Term Assets	2.5	4.67	1.09	0.45	1.43	0.33
Total Long-Term Assets	37.78	9.14	6.95	4.91	4.84	0.43
Total Assets	142.6	109.97	54.87	80.83	14.96	25.36
Accounts Payable	3.13	2.62	3.13	0.92	1.07	0.63
Deferred Revenue	13.79	15.35	11.72	0	0	0
Current Debt	5.43	1.55	1.07	0.99	0.9	0
Other Current Liabilities	-2.76	-5.05	2.33	2.98	3.24	1.33
Total Current Liabilities	19.6	14.47	18.25	4.88	5.21	1.96
Long-Term Debt	21.45	0.67	0.38	1.45	2.43	0
Other Long-Term Liabilities	12.14	14.08	1.93	0	0	0.12
Total Long-Term Liabilities	33.58	14.74	2.31	1.45	2.43	0.12
Total Liabilities	53.18	29.21	20.55	6.34	7.64	2.08
Total Debt	26.88	2.22	1.45	2.44	3.33	0
Debt Growth	1113.04%	52.51%	-40.43%	-26.67%	-	-
Retained Earnings	-311.36	-248.68	-193.4	-149.88	-127.76	-111.45
Comprehensive Income	0.03	0.01	0	0	0	0
Shareholders' Equity	89.42	80.75	34.32	74.49	-123.34	-107.07
Net Cash / Debt	77.26	97.07	44.62	72.48	6.81	24.22
Net Cash / Debt Growth	-20.40%	117.53%	-38.44%	964.20%	-71.88%	-
Net Cash Per Share	1.55	3.21	3.44	8.44	33.70	145.81
Working Capital	85.22	86.36	29.67	71.03	4.91	22.97
Book Value Per Share	1.79	2.67	2.64	8.67	-610.30	-644.70

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).